204 related articles for article (PubMed ID: 35992062)
1. EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression.
Gonzalez ME; Naimo GD; Anwar T; Paolì A; Tekula SR; Kim S; Medhora N; Leflein SA; Itkin J; Trievel R; Kidwell KM; Chen YC; Mauro L; Yoon E; Andò S; Kleer CG
iScience; 2022 Aug; 25(8):104827. PubMed ID: 35992062
[TBL] [Abstract][Full Text] [Related]
2. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis.
Anwar T; Arellano-Garcia C; Ropa J; Chen YC; Kim HS; Yoon E; Grigsby S; Basrur V; Nesvizhskii AI; Muntean A; Gonzalez ME; Kidwell KM; Nikolovska-Coleska Z; Kleer CG
Nat Commun; 2018 Jul; 9(1):2801. PubMed ID: 30022044
[TBL] [Abstract][Full Text] [Related]
3. Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
McMullen ER; Skala SL; Gonzalez ME; Djomehri S; Chandrashekar DS; Varambally S; Kleer CG
Breast Cancer; 2021 Mar; 28(2):496-505. PubMed ID: 33247371
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.
Kim E; Kim M; Woo DH; Shin Y; Shin J; Chang N; Oh YT; Kim H; Rheey J; Nakano I; Lee C; Joo KM; Rich JN; Nam DH; Lee J
Cancer Cell; 2013 Jun; 23(6):839-52. PubMed ID: 23684459
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.
Moore HM; Gonzalez ME; Toy KA; Cimino-Mathews A; Argani P; Kleer CG
Breast Cancer Res Treat; 2013 Apr; 138(3):741-52. PubMed ID: 23539298
[TBL] [Abstract][Full Text] [Related]
6. Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
Lawrence CL; Baldwin AS
PLoS One; 2016; 11(10):e0165005. PubMed ID: 27764181
[TBL] [Abstract][Full Text] [Related]
7. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
8. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
Chien YC; Liu LC; Ye HY; Wu JY; Yu YL
Am J Cancer Res; 2018; 8(3):422-434. PubMed ID: 29636998
[TBL] [Abstract][Full Text] [Related]
9. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
Anwar T; Gonzalez ME; Kleer CG
Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
[TBL] [Abstract][Full Text] [Related]
10. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
[TBL] [Abstract][Full Text] [Related]
11. EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation.
Jarome TJ; Perez GA; Hauser RM; Hatch KM; Lubin FD
J Neurosci; 2018 Aug; 38(35):7635-7648. PubMed ID: 30030400
[TBL] [Abstract][Full Text] [Related]
12. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
Marchesi I; Bagella L
World J Clin Oncol; 2016 Apr; 7(2):135-48. PubMed ID: 27081636
[TBL] [Abstract][Full Text] [Related]
13. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.
Yan J; Li B; Lin B; Lee PT; Chung TH; Tan J; Bi C; Lee XT; Selvarajan V; Ng SB; Yang H; Yu Q; Chng WJ
Blood; 2016 Aug; 128(7):948-58. PubMed ID: 27297789
[TBL] [Abstract][Full Text] [Related]
14. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
[TBL] [Abstract][Full Text] [Related]
15. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
Bae WK; Yoo KH; Lee JS; Kim Y; Chung IJ; Park MH; Yoon JH; Furth PA; Hennighausen L
Mol Carcinog; 2015 Oct; 54(10):1172-80. PubMed ID: 25043748
[TBL] [Abstract][Full Text] [Related]
16. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
17. Regulation and Role of EZH2 in Cancer.
Yamaguchi H; Hung MC
Cancer Res Treat; 2014 Jul; 46(3):209-22. PubMed ID: 25038756
[TBL] [Abstract][Full Text] [Related]
18. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
Hwang IJ; Park J; Seo SB
Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
[TBL] [Abstract][Full Text] [Related]
19. EZH2 methyltransferase and H3K27 methylation in breast cancer.
Yoo KH; Hennighausen L
Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
[TBL] [Abstract][Full Text] [Related]
20. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]